Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

Psoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: Klint, Susanne, Feldwisch, Joachim, Gudmundsdotter, Lindvi, Dillner Bergstedt, Karin, Gunneriusson, Elin, Höidén Guthenberg, Ingmarie, Wennborg, Anders, Nyborg, Andrew C., Kamboj, Amol P., Peloso, Paul M., Bejker, David, Frejd, Fredrik Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187109/
https://www.ncbi.nlm.nih.gov/pubmed/37184136
http://dx.doi.org/10.1080/19420862.2023.2209920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187109/
https://www.ncbi.nlm.nih.gov/pubmed/37184136
http://dx.doi.org/10.1080/19420862.2023.2209920

Ejemplares similares